{"commentary":{"count":27,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":18,"podcast":7,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03706365\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CYCLONE 2","nct_id":"NCT03706365","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cyclone-2-nct03706365. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CYCLONE 2","arms":[{"description":"Participants received 200 milligrams (mg) abemaciclib twice daily (BID) in combination with standard doses of 1000 mg abiraterone acetate once daily and 5 mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.","label":"Abemaciclib","type":"EXPERIMENTAL"},{"description":"Participants received placebo BID in combination with standard doses of 1000 mg abiraterone acetate once daily and 5 mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":393,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Abemaciclib","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Abiraterone acetate","type":"DRUG"},{"name":"Prednisone","type":"DRUG"}],"last_update":"2026-08-07","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2024-01-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Radiographic Progression Free Survival (rPFS)","timeFrame":"From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)"}],"references":[{"citation":"Smith M, Piulats J, Todenhofer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Flechon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N; CYCLONE 2 investigators. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025 Nov;26(11):1489-1500. doi: 10.1016/S1470-2045(25)00475-9.","pmid":"41167216","type":"DERIVED"}],"start_date":{"date":"2018-11-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03706365"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cyclone-2-nct03706365"}